Neuralstem gets U.S. patent covering the use of NSI-189 in MDD; shares up 3% premarket

• The USPTO issues a new patent to Neuralstem (CUR) covering protocols for using lead product candidate NSI-189 and related compounds for the treatment of major depressive disorder (MDD).
• Shares are up 3% premarket on turnover of 600 shares.